{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T19:37:36Z","timestamp":1773517056343,"version":"3.50.1"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Working Group on Cardio-oncology of the Korean Society of Cardiology","award":["2022-01-01"],"award-info":[{"award-number":["2022-01-01"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Although doxorubicin (DOX) is a commonly used potent chemotherapeutic agent in patients with breast cancer, its cardiotoxic effect is a concern, particularly in patients with hypertension. Antihypertensive renin-angiotensin system (RAS) inhibitors may potentially play a role in preventing overt heart failure (HF) due to DOX toxicity. This study aimed to evaluate whether the use of RAS inhibitors improves clinical outcomes in patients with hypertension and breast cancer undergoing DOX-containing chemotherapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A total of 54,344 female patients who were first diagnosed with breast cancer and initiated into DOX therapy between 2008 and 2015 were recruited from a nationwide Korean cohort. Patients were divided into two groups: with and without hypertension (HT, n = 10,789; non-HT, n = 43,555), and the RAS inhibitor group (n = 1,728) was sub-classified from the HT group. Two propensity score-matched cohorts were constructed to compare the clinical outcomes between non-HT and HT groups and between non-HT and RAS inhibitor groups. The primary outcome was the composite of HF and death.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>After propensity score matching, the HT group had a higher risk for HF (adjusted hazard ratio [HR] = 1.30, 95% confidence intervals [95% CI] = 1.09\u20131.55) compared to the non-HT group, but there was no significant difference in primary outcome between the two groups. The RAS inhibitor group had a lower risk for primary outcome (adjusted HR = 0.78, 95% CI = 0.65\u20130.94) and death (adjusted HR = 0.81, 95% CI = 0.66\u20130.99) compared to the non-HT group.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Hypertension is a risk factor for HF in patients with breast cancer undergoing DOX chemotherapy. However, the RAS inhibitors used to treat hypertension may contribute to decreased mortality and improved clinical outcomes.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0294649","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T18:31:35Z","timestamp":1700505095000},"page":"e0294649","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact on clinical outcomes of renin-angiotensin system inhibitors against doxorubicin-related toxicity in patients with breast cancer and hypertension: A nationwide cohort study in South Korea"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3577-524X","authenticated-orcid":true,"given":"Hui-Jeong","family":"Hwang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3765-5655","authenticated-orcid":true,"given":"Taek-Gu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"key":"pone.0294649.ref001","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).","volume":"43","author":"AR Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"pone.0294649.ref002","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","article-title":"Evaluation and management of patients with heart disease and cancer: cardio-oncology","volume":"89","author":"J Herrmann","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"pone.0294649.ref003","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","article-title":"Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin\u2019s lymphoma.","volume":"26","author":"DL Hershman","year":"2008","journal-title":"J Clin Oncol"},{"key":"pone.0294649.ref004","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jash.2014.08.009","article-title":"Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma.","volume":"8","author":"S Szmit","year":"2014","journal-title":"J Am Soc Hypertens"},{"key":"pone.0294649.ref005","doi-asserted-by":"crossref","first-page":"664741","DOI":"10.3389\/fonc.2021.664741","article-title":"Angiotensin System Inhibitors May Improve Outcomes of Patients With Castration-Resistant Prostate Cancer During Abiraterone Acetate Treatment-A Cardio-Oncology Study.","volume":"11","author":"M Wilk","year":"2021","journal-title":"Front Oncol"},{"key":"pone.0294649.ref006","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/s12967-020-02564-w","article-title":"Prophylactic, single-drug cardioprotection in a comparative, experimental study of doxorubicin-induced cardiomyopathy.","volume":"18","author":"M L\u00f3di","year":"2020","journal-title":"J Transl Med"},{"key":"pone.0294649.ref007","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12967-019-1978-0","article-title":"Advantages of prophylactic versus conventionally scheduled heart failure therapy in an experimental model of doxorubicin-induced cardiomyopathy","volume":"17","author":"M L\u00f3di","year":"2019","journal-title":"J Transl Med"},{"key":"pone.0294649.ref008","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","article-title":"Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition","volume":"114","author":"D Cardinale","year":"2006","journal-title":"Circulation"},{"key":"pone.0294649.ref009","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.","volume":"37","author":"G Gulati","year":"2016","journal-title":"Eur Heart J"},{"key":"pone.0294649.ref010","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10741-019-09906-x","article-title":"Effects of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker use on cancer therapy-related cardiac dysfunction: a meta-analysis of randomized controlled trials","volume":"26","author":"K Fang","year":"2021","journal-title":"Heart Fail Rev"},{"key":"pone.0294649.ref011","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11739-020-02508-8","article-title":"Prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis.","volume":"16","author":"F Caspani","year":"2021","journal-title":"Intern Emerg Med"},{"key":"pone.0294649.ref012","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1093\/annonc\/mdv147","article-title":"Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma","volume":"26","author":"H Izzedine","year":"2015","journal-title":"Ann Oncol"},{"key":"pone.0294649.ref013","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-14-2332","article-title":"Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma","volume":"21","author":"RR McKay","year":"2015","journal-title":"Clin Cancer Res"},{"key":"pone.0294649.ref014","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.clgc.2016.12.016","article-title":"Angiotensin Inhibitors as Treatment of Sunitinib\/Pazopanib-induced Hypertension in Metastatic Renal Cell Carcinoma.","volume":"15","author":"P Penttil\u00e4","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"pone.0294649.ref015","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/CEJ.0000000000000269","article-title":"The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: a meta-analysis.","volume":"26","author":"T Song","year":"2017","journal-title":"Eur J Cancer Prev"},{"key":"pone.0294649.ref016","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3109\/07357907.2011.616252","article-title":"Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and\/or statins.","volume":"29","author":"YK Chae","year":"2011","journal-title":"Cancer Invest"},{"key":"pone.0294649.ref017","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10549-011-1505-3","article-title":"Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: results from the LACE cohort","volume":"129","author":"PA Ganz","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"pone.0294649.ref018","doi-asserted-by":"crossref","first-page":"492","DOI":"10.4048\/jbc.2023.26.e34","article-title":"Differential cardiovascular outcomes of each antihypertensive drug class in patients with hypertension and breast cancer undergoing doxorubicin-containing chemotherapy","volume":"26","author":"HJ Hwang","year":"2023","journal-title":"J Breast Cancer"},{"key":"pone.0294649.ref019","first-page":"253","article-title":"Heart failure in the general population of men\u2014morbidity, risk factors and prognosis","volume":"249","author":"L Wilhelmsen","year":"2001","journal-title":"J Intern Med"},{"key":"pone.0294649.ref020","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.1996.03530440037034","article-title":"The progression from hypertension to congestive heart failure","volume":"275","author":"D Levy","year":"1996","journal-title":"JAMA"},{"key":"pone.0294649.ref021","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41371-020-0391-8","article-title":"Hypertension management in cardio-oncology","volume":"34","author":"H Essa","year":"2020","journal-title":"J Hum Hypertens"},{"key":"pone.0294649.ref022","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1254\/jjp.88.183","article-title":"Beneficial effects of angiotensin-converting enzyme inhibition in adriamycin-induced cardiomyopathy in hamsters","volume":"88","author":"K Okumura","year":"2002","journal-title":"Jpn J Pharmacol"},{"key":"pone.0294649.ref023","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0300-483X(94)90176-7","article-title":"Effects of ICRF-186 [(L)1,2-bis(3,5-dioxopiperazinyl-1-yl)propane] on the toxicity of doxorubicin in spontaneously hypertensive rats.","volume":"92","author":"J Zhang","year":"1994","journal-title":"Toxicology"},{"key":"pone.0294649.ref024","doi-asserted-by":"crossref","first-page":"e48771","DOI":"10.1371\/journal.pone.0048771","article-title":"Inhibition of cyclooxygenase-2 reduces hypothalamic excitation in rats with adriamycin-induced heart failure","volume":"7","author":"M Zheng","year":"2012","journal-title":"PLoS One"},{"key":"pone.0294649.ref025","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3109\/10715762.2010.509399","article-title":"Beneficial effects of angiotensin II receptor blocker, olmesartan, in limiting the cardiotoxic effect of daunorubicin in rats","volume":"44","author":"W Arozal","year":"2010","journal-title":"Free Radic Res"},{"key":"pone.0294649.ref026","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/jcp.25905","article-title":"Mitochondrial ROS-induced ERK1\/2 activation and HSF2-mediated AT1 R upregulation are required for doxorubicin-induced cardiotoxicity","volume":"233","author":"CY Huang","year":"2018","journal-title":"J Cell Physiol"},{"key":"pone.0294649.ref027","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/aps.2011.96","article-title":"Regulation of angiotensin-(1\u20137) and angiotensin II type 1 receptor by telmisartan and losartan in adriamycin-induced rat heart failure.","volume":"32","author":"WN Zong","year":"2011","journal-title":"Acta Pharmacol Sin"},{"key":"pone.0294649.ref028","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10741-020-09977-1","article-title":"Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications","volume":"27","author":"P Sobczuk","year":"2022","journal-title":"Heart Fail Rev"},{"key":"pone.0294649.ref029","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies).","volume":"61","author":"X Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"pone.0294649.ref030","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"PA Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"pone.0294649.ref031","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: \u2002The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).","volume":"37","author":"JL Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"pone.0294649.ref032","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1097\/00005344-200411000-00016","article-title":"Vascular endothelial growth factor-induced nitric oxide- and PGI2-dependent relaxation in human internal mammary arteries: a comparative study with KDR and Flt-1 selective mutants","volume":"44","author":"W Wei","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"key":"pone.0294649.ref033","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/S1470-2045(13)70464-9","article-title":"Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial","volume":"14","author":"BI Rini","year":"2013","journal-title":"Lancet Oncol"},{"key":"pone.0294649.ref034","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/annonc\/mdm184","article-title":"Hypertension as a predictive factor of Sunitinib activity","volume":"18","author":"O Rixe","year":"2007","journal-title":"Ann Oncol"},{"key":"pone.0294649.ref035","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/jch.12273","article-title":"Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis","volume":"16","author":"Y Li","year":"2014","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"pone.0294649.ref036","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3109\/0284186X.2010.543696","article-title":"Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma","volume":"50","author":"P Bono","year":"2011","journal-title":"Acta Oncol"},{"key":"pone.0294649.ref037","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbamcr.2016.03.010","article-title":"Overexpression of angiotensin II type 1 receptor in breast cancer cells induces epithelial-mesenchymal transition and promotes tumor growth and angiogenesis","volume":"1863","author":"E Oh","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"pone.0294649.ref038","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.18632\/aging.102032","article-title":"AGTR1 promotes lymph node metastasis in breast cancer by upregulating CXCR4\/SDF-1\u03b1 and inducing cell migration and invasion.","volume":"11","author":"Y Ma","year":"2019","journal-title":"Aging (Albany NY)"},{"key":"pone.0294649.ref039","doi-asserted-by":"crossref","first-page":"736361","DOI":"10.3389\/fendo.2021.736361","article-title":"The Effect of Local Renin Angiotensin System in the Common Types of Cancer.","volume":"12","author":"M Almutlaq","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"pone.0294649.ref040","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1179\/1973947815Y.0000000055","article-title":"Angiotensin II receptor antagonist olmesartan and NF-kappaB inhibitor as cytotoxic and apoptotic agents in MCF-7 human cell line.","volume":"28","author":"E Bakhtiari","year":"2016","journal-title":"J Chemother"},{"key":"pone.0294649.ref041","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s13277-014-2713-3","article-title":"Effect of angiotensin receptor blockade on prevention and reversion of tamoxifen-resistant phenotype in MCF-7 cells","volume":"36","author":"S Namazi","year":"2015","journal-title":"Tumour Biol"},{"key":"pone.0294649.ref042","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"SM Swain","year":"2003","journal-title":"Cancer"},{"key":"pone.0294649.ref043","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/CIRCULATIONAHA.112.100560","article-title":"Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues","volume":"126","author":"MG Khouri","year":"2012","journal-title":"Circulation"},{"key":"pone.0294649.ref044","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40885-023-00243-8","article-title":"Korea hypertension fact sheet 2022: analysis of nationwide population-based data with a special focus on hypertension in the elderly.","volume":"29","author":"HC Kim","year":"2023","journal-title":"Clin Hypertens"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0294649","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T18:32:08Z","timestamp":1700505128000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0294649"}},"subtitle":[],"editor":[{"given":"Amirmohammad","family":"Khalaji","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":44,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0294649","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,20]]}}}